Facts and Fictions About [18F]FDG versus Other Tracers in Managing Patients with Brain Tumors: It Is Time to Rectify the Ongoing MisconceptionsAn Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non-Thyroid Endocrine Neoplasms18F-Fluorodeoxyglucose-PET-Computerized Tomography and non-Fluorodeoxyglucose PET-Computerized Tomography in Hepatobiliary and Pancreatic MalignanciesMolecular Imaging Assessment of Androgen Deprivation Therapy in Prostate CancerMolecular Imaging Assessment of Hormonally Sensitive Breast Cancer: An Appraisal of 2- [18F]-Fluoro-2-Deoxy-Glucose and Newer Non-2-[18F]-Fluoro-2-Deoxy-Glucose PET Tracers18F-FDG Versus Non-FDG PET Tracers in Multiple MyelomaRole of Molecular Imaging with PET/MR Imaging in the Diagnosis and Management of Brain TumorsFibroblast Activation Protein Inhibitor TheranosticsPET-CTBased Quantitative Parameters for Assessment of Treatment Response and Disease Activity in Cancer and Noncancerous DisordersPositron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such SettingsNonmalignant Thoracic Disorders: An Appraisal of Fluorodeoxyglucose and Non>fluorodeoxyglucose PET/Computed Tomography ApplicationsFluorodeoxyglucose PET/Computed Tomography in Evaluation of Prosthetic Joints and Diabetic Foot: A Comparative Perspective with Other Functional Imaging ModalitiesUtility of PET/Computed Tomography in Infection and Inflammation ImagingRole of Fluorodeoxyglucose-PET in Interventional Radiology